Holtec Nuclear delays IPO as Nscale eyes multibillion dollar debut
Holtec Nuclear abruptly postponed its $825 million IPO while Nscale filed for a potential $2 billion offering and Electra Therapeutics suffered a rare biotech IPO drop.
Nasdaq Biotechnology Index 1 article
The Nasdaq Biotechnology Index is an equity-market benchmark composed of biotechnology and pharmaceutical companies listed on Nasdaq under defined eligibility and weighting rules. It is used to track the performance of a broad public-biotech basket rather than the prospects of one company or therapeutic modality. For biotechnology analysis, the index provides sector-level context for relative performance, investor risk appetite and comparisons between individual public companies and the wider listed biopharma market.